Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes. / Niazi, Siar; Gnesin, Filip; Thein, Anna-Sophie; Andreasen, Jens R; Horwitz, Anna; Mouhammad, Zaynab A; Jawad, Baker N; Niazi, Zia; Pourhadi, Nelsan; Zareini, Bochra; Meaidi, Amani; Torp-Pedersen, Christian; Kolko, Miriam.
In: Ophthalmology, Vol. 131, No. 9, 2024, p. 1056-1063.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes
AU - Niazi, Siar
AU - Gnesin, Filip
AU - Thein, Anna-Sophie
AU - Andreasen, Jens R
AU - Horwitz, Anna
AU - Mouhammad, Zaynab A
AU - Jawad, Baker N
AU - Niazi, Zia
AU - Pourhadi, Nelsan
AU - Zareini, Bochra
AU - Meaidi, Amani
AU - Torp-Pedersen, Christian
AU - Kolko, Miriam
N1 - Copyright © 2024. Published by Elsevier Inc.
PY - 2024
Y1 - 2024
N2 - PURPOSE: To examine the association between Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) use and the development of glaucoma in individuals with type 2 diabetes.DESIGN: Nationwide, nested case-control study.PARTICIPANTS: From a nationwide cohort of 264708 individuals, we identified 1,737 incident glaucoma cases and matched them to 8685 glaucoma-free controls, all aged above 21 years old and treated with metformin and a second-line antihyperglycemic drug formulation, with no history of glaucoma, eye trauma or eye surgery.METHODS: Cases were incidence density matched to five controls by birth year, sex, and date of second-line treatment initiation.MAIN OUTCOME MEASURES: Conditional logistic regression was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for glaucoma, defined by first-time diagnosis, first-time use of glaucoma-specific medication, or first-time glaucoma-specific surgical intervention.RESULTS: Compared with the reference group, who received treatments other than GLP-1RA, individuals who were exposed to GLP-1RA treatment exhibited a lower risk of incident glaucoma (HR: 0.81, CI: 0.70 - 0.94, p = 0.006). Prolonged treatment extending beyond three years lowered the risk even further (HR: 0.71, CI: 0.55 - 0.91, p = 0.007). Treatment with GLP-1RA for 0 - 1 years (HR: 0.89, CI: 0.70 - 1.14, p = 0.35) and 1 - 3 years (HR: 0.85, CI: 0.67 - 1.06, p = 0.15) were not significant.CONCLUSIONS: GLP-1RA exposure was associated with a lower risk of developing glaucoma compared to receiving other second-line antihyperglycemic medication.
AB - PURPOSE: To examine the association between Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) use and the development of glaucoma in individuals with type 2 diabetes.DESIGN: Nationwide, nested case-control study.PARTICIPANTS: From a nationwide cohort of 264708 individuals, we identified 1,737 incident glaucoma cases and matched them to 8685 glaucoma-free controls, all aged above 21 years old and treated with metformin and a second-line antihyperglycemic drug formulation, with no history of glaucoma, eye trauma or eye surgery.METHODS: Cases were incidence density matched to five controls by birth year, sex, and date of second-line treatment initiation.MAIN OUTCOME MEASURES: Conditional logistic regression was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for glaucoma, defined by first-time diagnosis, first-time use of glaucoma-specific medication, or first-time glaucoma-specific surgical intervention.RESULTS: Compared with the reference group, who received treatments other than GLP-1RA, individuals who were exposed to GLP-1RA treatment exhibited a lower risk of incident glaucoma (HR: 0.81, CI: 0.70 - 0.94, p = 0.006). Prolonged treatment extending beyond three years lowered the risk even further (HR: 0.71, CI: 0.55 - 0.91, p = 0.007). Treatment with GLP-1RA for 0 - 1 years (HR: 0.89, CI: 0.70 - 1.14, p = 0.35) and 1 - 3 years (HR: 0.85, CI: 0.67 - 1.06, p = 0.15) were not significant.CONCLUSIONS: GLP-1RA exposure was associated with a lower risk of developing glaucoma compared to receiving other second-line antihyperglycemic medication.
U2 - 10.1016/j.ophtha.2024.03.004
DO - 10.1016/j.ophtha.2024.03.004
M3 - Journal article
C2 - 38490274
VL - 131
SP - 1056
EP - 1063
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 9
ER -
ID: 385888423